Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 2:6:36149.
doi: 10.1038/srep36149.

Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer

Affiliations

Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer

Artur Mezheyeuski et al. Sci Rep. .

Abstract

The complexity of tumor histomorphology reflects underlying tumor biology impacting on natural course and response to treatment. This study presents a method of computer-aided analysis of tissue sections, relying on multifractal (MF) analyses, of cytokeratin-stained tumor sections which quantitatively evaluates of the morphological complexity of the tumor-stroma interface. This approach was applied to colon cancer collection, from an adjuvant treatment randomized study. Metrics obtained with the method acted as independent markers for natural course of the disease, and for benefit of adjuvant treatment. Comparative analyses demonstrated that MF metrics out-performed standard histomorphological features such as tumor grade, budding and configuration of invasive front. Notably, the MF analyses-derived "αmax" -metric constitutes the first response-predictive biomarker in stage II-III colon cancer showing significant interactions with treatment in analyses using a randomized trial-derived study population. Based on these results the method appears as an attractive and easy-to-implement tool for biomarker identification.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1. Representative images from cases with low and high MF metrics scores.
Two tumors are shown after pan-cytokeratin staining and after completion of “contour-formation”. Cases are selected to illustrate low and high MF metrics scores. αmax and f(α)max scores are shown as for ‘outline’-based and ‘internal structure’-bases image analyses.
Figure 2
Figure 2. Survival-associations for MF metrics and histomorphological scores in stage II-III colon cancer treated with surgery alone.
(A) Association between MF metrics (αmax and f(α)max), histomorphological features and TTR. Cox regression analyses were used for determination of HRs. (B) Kaplan-Meier plots illustrating TTR of stage II-III colon cancer treated with surgery alone after median-based dichotomization of cases based on the f(α)max metric. All MF metric-related analyses were performed with median-based dichotomization of cases into “metric-high” and “metric-low” groups.
Figure 3
Figure 3. Treatment-efficacy in MF-metric-defined subgroups of stage II-III colon cancer.
(Left and middle part) Kaplan-Meier plots illustrating TTR of stage II-III colon cancer patients receiving surgery alone (red lines) or surgery together with adjuvant chemotherapy after dichotomization of the study cohort based on αmax (upper part), or f(α)max (lower part). Log-rank test was used for statistical analyses. (Right part) Interaction between MF metrics and treatment were analyzed using “formal interaction test”. All MF metric-related analyses were based on median-based dichotomization of cases into “metric-high” and “metric-low” groups.

Similar articles

Cited by

References

    1. Dienstmann R., Salazar R. & Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 33, 1787–1796, doi: 10.1200/JCO.2014.60.0213 (2015). - DOI - PubMed
    1. Pahlman L. A. et al. Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated? J Clin Oncol 34, 1297–1299, doi: 10.1200/JCO.2015.65.3048 (2016). - DOI - PubMed
    1. Benson A. B. 3rd et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22, 3408–3419, doi: 10.1200/JCO.2004.05.063 (2004). - DOI - PubMed
    1. Schmoll H. J. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23, 2479–2516, doi: 10.1093/annonc/mds236 (2012). - DOI - PubMed
    1. Pahlman L. A. et al. Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated? J Clin Oncol, doi: 10.1200/JCO.2015.65.3048 (2016). - DOI - PubMed

Publication types